August 2021

REGENERON CORPORATE PRESENTATION

REGENERON[®]


CONFIDENTIAL

Note Regarding Forward-Looking Statements & Non-GAAP Financial Measures


This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "olan," "believe," "seek," estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators' ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators (collectively, "Regeneron's Products"), and the global economy: the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates being developed by Regeneron and/or its collaborators (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation EYLEA® (affibercept) Injection, Dupixent® (dupilumab), Libtayo[®] (cemiplimab), Praluent[®] (alirocumab), Evkeeza[™] (evinacumab), Inmazeb[™] (atoltivimab, and odesivimab-ebgn), REGEN-COV[™] (casirivimab and imdevimab), fasinumab, garetosmab, pozelimab, odronextamab, itepekimab, REGN5458, REGN5713-5714-5715, Regeneron's other oncology programs (including its costimulatory bispecific portfolio). Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; safety issues resulting from the administration of Regeneron's Products and Regeneron's Pr and Regeneron's Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, including without limitation those listed above: the likelihood and timing of achieving any of the anticipated milestones described in this presentation; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval: ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs. and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates: competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates: uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of Regeneron's Products and Regeneron's Product Candidates; the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid: coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance: risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA. Dupixent. Praluent, and REGEN-COV), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition; and the potential for any license or collaboration agreement, including Regeneron's acreements with Sanofi. Baver, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), as well as Regeneron's acreement with Roche relating to the casirivimab and imdevimab antibody cocktail (known as REGEN-COV in the United States and RonapreveTM in other countries), to be cancelled or terminated. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (oublicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise,

This presentation uses non-GAAP net income per share, or non-GAAP EPS, and net cash, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"). These and other non-GAAP financial measures are computed by excluding certain non-cash and other items from the related GAAP financial measure. Non-GAAP adjustments also include the income tax effect of reconciling items. The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance. For example, adjustments may be made for items that fluctuate from period based on factors that are not within the Company's control, such as the Company's stock price on the dates share-based grants are issued. Management uses non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis. Additionally, non-GAAP measures provide investors with an enhanced understanding of the financial measures may not be company's core business operations. However, there are limitations in the use of non-GAAP financial measures as they exclude certain expenses that are recurring in nature. Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP financial measures used in this presentation is provided on slide 27.

REGENERON A Diversified Growth Story



Strong Execution in 2Q 2021



PDUFA - Prescription Drug User Fee Act; OS - Overall Survival

CSU - Chronic Spontaneous Urticaria

R&D Pipeline Advancements



RTAYC (cemiplimab-rwlc) Injection 350 ma

Revenue attributable to REGEN-COV™ and Ronapreve™: \$2,76B

Pediatric Asthma (PDUFA 10/21/21

Positive Ph3 results in CSU

OS benefit when combined with chemotherapy in 1L NSCI C

Initial data for I AG-3 + Libtayo showed 66.7% ORR in PDL-1 Naïve patients

EUA expanded to include postexposure prophylaxis

Reduced risk of death 20% in hospitalized patients in UK **RECOVERY** study

This slide contains investigational products not yet approved by regulatory authorities

EYLEA, Dupixent, and Oncology are Core to Diversified Growth Strategy

Specialized programs offer additional growth potential

EYLEA	Dupixent*	Oncology	Specialized growth opportunities:
 Execute and grow in wet AMD and 	Transform treatment of Type 2	 Realize potential for best-in-class 	Infectious Disease COVID-19 [^] & Ebola Antibody Cocktails
diabetic eye diseasesExplore high-dose formulation for less	inflammatory diseasesRealize full potential in AD, asthma and	immunotherapy treatments • <u>Compete</u> , <u>Enhance</u> ,	Rare Disease HoFH, C5-mediated diseases+
 frequent dosing Pursue gene therapy and other novel 	sue gene therapy • Execute broad Ph3 &	and <u>Extend</u> benefits of immunotherapy to broader patient populations	Allergic Disease Cat, Birch
approaches			Genetic Medicine CRISPR/CAS9**, siRNA†


5

* In collaboration with Sanofi ^ In collaboration with Roche † In collaboration with Alnylam ** In collaboration with Intellia



EYLEA®: Extending Leadership Position

Setting a high bar on efficacy/safety/convenience for current and future potential competition



U.S. Net Product Sales, \$Billion

#1 prescribed anti-VEGF treatment 40+ million doses

administered since launch

Extending Category Leadership

- 2Q21 U.S. net product sales of \$1.42Bn (+28% YoY)
- Sales gains and favorable demographic trends

Maximize Growth Initiatives

- Realize potential in diabetic eye diseases
- Initiating DTC to drive disease awareness

Focusing on the Science

- Explore high-dose aflibercept for less frequent dosing
- Pursue gene therapy and other novel approaches




6

Dupixent®: Strong Growth Trajectory



+59% worldwide sales growth in 2Q21 vs. 2Q20



Broad-based growth across all approved indications

Significant market opportunities support future growth

Advancing clinical development program across EIGHT Type 2 diseases



REGENERON

Net Product Sales*, \$Million

Dupixent®: Driving Leverage in Collaboration Profitability

Antibody Collaboration Share of Profits / (Losses)*

(in Millions)




REGENERON

8

* Share of profits/(losses) are derived from global net product sales of Praluent (up until and including 1Q20), Kevzara, and Dupixent, recorded by Sanofi

Substantial Patient Opportunity in Type 2 Inflammatory Diseases for Dupixent[®]



CRSwNP – Chronic Rhinosinusitis with Nasal Polyposis; COPD – Chronic Obstructive Pulmonary Disease; CRSsNP – Chronic Rhinosinusitis without Nasal Polyposis

9

Figures represent U.S. Biologic-eligible target population (all age groups); dates represent expected first submission *Target population includes age groups that are not currently approved but in clinical development Source – Regeneron Internal Epidemiology Data

Dupixent & Itepekimab (anti IL-33) COPD Phase 3s Underway

Two-pronged approach against COPD

Dupixent addresses Type 2 COPD

Achieved prespecified efficacy milestone in interim analysis of first Ph3 study

Eosinophils ≥300/µl

Both former and current

2 Ph3 trials ongoing

Pivotal data expected 2

Itepekimab addresses

Recently published Ph2 proofbenefit in former smokers, rega

No eosinophil restriction

Focus on former smoke

2 Ph3 trials ongoing

10

Pivotal data expected 2024

y milestone minite	enin analysis of	Non-Type 2	Type 2
nt smokers <u>2023</u> s also non-T y	Former Smokers (70% of COPD patients^)	Itepekimab only ~600K patients	Dupixent or Itepekimab >350K patients
	, showed potential		Dupixent only ~150K patients

Dupixent and Itepekimab are developed in collaboration with Sanofi; COPD - Chronic Obstructive Pulmonary Disease * Rabe et al. Lancet Respir Med. 2021

^ US. EU and Japan epidemiology, patient populations exclude never smokers (Regeneron Internal Epidemiology Data)



Libtayo - Foundational Therapy to Our Oncology Strategy

<u>COMPETE</u>, ENHANCE, and EXTEND treatment benefits in monotherapy and combination settings

Dermato-oncology


- First approved anti-PD-1 in advanced CSCC; adjuvant studies enrolling
- FDA and EMA Approved as first-in-class anti-PD-1 in advanced BCC
- Positive clinical data in combination with fianlimab (anti-LAG3) in advanced melanoma

Non-Small Cell Lung Cancer

- FDA and EMA Approved in 1L NSCLC (PD-L1 \geq 50%)
- Overall survival benefit in combination with chemotherapy regardless of PD-L1 expression

2L Cervical Cancer

- 1st immunotherapy to demonstrate improvement in overall survival
- Regulatory submissions expected in 2H21




* Sanofi records net product sales of LIBTAYO outside the U.S.

This slide contains investigational products not yet approved by regulatory authorities



Oncology Strategy: Aspire to Compete, Enhance, & Extend



COMPETE

LIBTAYO delivers potentially 'best-inclass' data in tumors responsive to PD-1 monotherapy

ENHANCE

Even for PD-1 responsive tumors, more than half of patients do not respond

EXTEND

Many tumor settings have limited responses to checkpoint inhibition


Significant Opportunity to Enhance & Extend Treatment Benefits

Despite the advancements in the field, there are many cancers that don't respond to anti PD-1 monotherapy


Even for those cancers that are responsive, many patients unfortunately do not benefit

Regeneron's clinical development pipeline of 12+ candidates has potential to address unmet need of the most prevalent cancer types


Number of Cancer Cases Per Year



Regeneron's Oncology Toolkit Provides Unique Combinatorial Flexibility



Bispecifics For Hematologic Cancers



Potential best-in-class efficacy*

R/R Follicular Lymphoma


• ORR=90%, CR=70%

R/R DLBCL (CAR-T naïve)

• ORR=55%, CR=55%


R/R DLBCL (post-CAR-T) • ORR=33%, CR=21%

Patient enrollment has resumed for FL and DLBCL in potentially pivotal monotherapy trials




Expand investigation of potential best-in-class bispecific into earlier lines of multiple myeloma

R/R Multiple Myeloma* 3-12mg: ORR=29%, VGPR or better= 25% 24-48mg: ORR=41%, VGPR or better= 41% 96mg: ORR=63%, VGPR or better= 63%



Bispecifics for Solid Tumors: Enhance And Extend Benefits Of Checkpoint Inhibitors



Combinations of our CD3 and CD28 bispecific antibodies and checkpoint inhibitors offer advantage of simultaneously providing multiple signals for activating T cells to kill tumors

Robust combinatorial potential and flexibility to enhance and extend treatment across many different types of cancers

Broad Oncology Pipeline & Combinations Continue to Advance

ONGOING	LIBTAYO*			Advanced Lung cancer (chemo combo); Adjuvant CSCC	
	REGN3767 (LAG-3)	+	LIBTAYO*	Advanced melanoma	
	REGN6569 (GITR)	+ -	LIBTAYO*	Solid tumors	
	REGN4018 (MUC16xCD3)	+	LIBTAYO*	2+ line Ovarian cancer	
	REGN5668 (MUC16xCD28)	+	REGN4018 / LIBTAYO*	2+ line Ovarian cancer	
	REGN5678 (PSMAxCD28)	+	LIBTAYO*	3+ line Prostate cancer	
	REGN7075 (EGFRxCD28)	+	LIBTAYO*	Solid tumors	
	REGN5093 (METxMET)			Advanced MET altered Lung cancer	
	Odronextamab (CD20xCD3)			3+ line Lymphoma	
	Odronextamab (CD20xCD3)	+/-	LIBTAYO*	3+ line Lymphoma	
	REGN5458/9 (BCMAxCD3)			3+ line Multiple myeloma	
UPCOMING	PSMAxCD3	+	REGN5678/LIBTAYO*	Prostate cancer	
	REGN5093-M114 (METxMET ADC)			Advanced MET altered Lung cancer	
	odronextamab (CD20xCD3)	+	B cell/CD28 costim	B-NHL	
	odronextamab (CD20xCD3)	+	Standard of Care	B-NHL	
	REGN5458/9 (BCMAxCD3)	+	Plasma cell/CD28 costim	Multiple myeloma	
	REGN5458/9 (BCMAxCD3)	+ -	Standard of Care	Multiple myeloma	
c <i>lmmune®</i> Antiboo	dies Anti-PD-1		CD3 BiSpecifics	Costim BiSpecifics New BiSpe	
* In cr	Illaboration with Sanofi		This slide contains investiga	ational products not yet approved by regulatory authorities	

* In collaboration with Sanofi

17

This slide contains investigational products not yet approved by regulatory authorities

The first COVID-19 combination therapy to receive EUA



Efficacy

REGEN-COV (casirivimab and imdevimab)

- EUA granted for 1.2g dose (for subcutaneous / IV administration) in high-risk, non-hospitalized patients after showing 70% reduction in deaths or hospitalizations
- EUA granted for post-exposure prophylaxis in certain patients after showing reduction in symptomatic infections by 81%
- UK RECOVERY study showed REGEN-COV reduced risk of death by 20% in seronegative hospitalized patients*
- Retains potency against all known variants

Supply

- Supplied **over 1.5 million doses** of REGEN-COV to the U.S. Government across two supply agreements
- Partnered with Roche to manufacture and distribute Ronapreve[™] outside of the U.S. and to ensure availability in low- and middle-income countries

Upcoming Milestones

- FDA decision regarding expansion of EUA to include preexposure prophylaxis indication
- FDA decision regarding expansion of EUA to include hospitalized indication
- $\circ~$ Complete rolling BLA and MAA submissions in 2H 2021



Evkeeza: Rare Disease Opportunity

Address Unmet Need in Patients with HoFH



Now Approved

Build Rare Disease Strategy


Apply Cardiometabolic Expertise



Found that patients with loss-of-function mutations in their ANGPTL3 gene have significantly lower levels of key blood lipids, including LDL-C

Evinacumab was designed to replicate this loss-of-function mutation effect to lower LDL-C in patients with HoFH

Supercharging the Future of Genetics and Turnkey Therapeutics Platforms at Regeneron



Regeneron is investing in and delivering technologies well beyond antibodies

- 3 genetics medicines programs in the clinic
- **3-5** additional potential targets to advance to IND-enabling studies in next 12 months
- 30+ additional programs in research and candidate selection phase
- **10+** novel genetic targets discovered

Several near-term opportunities emerging from Regeneron Genetics Medicines:

- Reported landmark TTR genome editing data in Jun'21
- C5 combo program Ph3 start (Myasthenia Gravis in 2H21, PNH in 2022)
- HSD17B13 siRNA healthy volunteer data readout in 2H21
- APP siRNA Ph1 start for Alzheimer's
- DB-OTO gene therapy (hearing loss) Ph1/2 start in 2022

REGENERON GENETICS MEDICINES

Building the Pipeline for the Future

POZELIMAB +

CEMDISIRAN¹

CEMDISIRAN¹

C5 siRNA

C5 Antibody + C5 siRNA

Paroxysmal Nocturnal

Myasthenia Gravis

Hemoglobinuria

Immunoglobulin A

Nephropathy

Pre-IND

Clinical Development

FACTOR 8 GENE INSERTION² CRISPR/Cas9 + AAV Transgene Insertion • Hemophilia A

PNPLA3¹ PNPLA3 siRNA

 Nonalcoholic Steatohepatitis

DB-OTO³ OTOF AAV Dual Vector Gene Therapy

OTOF Related Hearing Loss

FACTOR 9 GENE INSERTION² CRISPR/Cas9 + AAV Transgene Insertion

Hemophilia B

ALN-APP¹

- APP siRNA
- Alzheimer's Disease

ADDITIONAL PROGRAMS 30+ Programs in Research and Candidate Selection

Alnylam Pharmaceuticals Intellia Therapeutics Decibel Therapeutics

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

ALN-HSD¹

 HSD17B13 siRNA
 Nonalcoholic Steatohepatitis

NTLA-2001² CRISPR/Cas9

 Hereditary Transthyretin Amyloidosis with Polyneuropathy




Genome Editing – Knockout: TTR Collaboration With Intellia

First Human Proof-of-Concept Achieved for First Systemic CRISPR-based Therapeutic

- First-in-human data validate our CRISPR-based TTR knockout approach
 - Single dose with NTLA-2001 led to dosedependent reductions in serum TTR
 - Mean serum TTR reduction of 87% at 0.3 mg/kg dose, including one patient with 96% reduction
 - No serious adverse events observed in the first six patients by day 28

Proof-of-Concept With TTR Increases Probability of Success for Both Knockout and Insertion Programs

- REGN has exclusive rights to Intellia's CRISPR technology for therapies targeting the liver*
 - 20+ preclinical programs under evaluation
- REGN has license to commercialize up to 10 ex vivo CRISPR products in defined cell types



*REGN has rights to develop up to 15 *in vivo* products; except certain named targets



Capital Allocation Priorities Leverage Financial Strength to Drive Long-Term Growth and Shareholder Value

- 1. Invest in our best-in-class R&D capabilities
- 2. <u>Pursue</u> and fund business development opportunities to enable and synergize our R&D capabilities and technologies
- 3. <u>Return</u> cash to shareholders through share repurchases

2Q21 Net Cash Position*: \$5.1B


\$289M in share repurchases in 2Q21 ~\$900M remains on \$1.5B share repurchase program



Regeneron-Discovered, Approved and Investigational Medicines Across a Wide and Diverse Set of Diseases

(afflibercept) Injection For Intravitreal Injection	(alirocumab) Injection Target (alirocumab) Injection Target		racumab-dgnb) REGEN-COV
 PHASE 1 REGEN-COV[*] (SARS-CoV-2) Fianlimab (LAG-3) REGN6569 (GITR) REGN5093 (MET×MET) REGN4018 (MUC16×CD3) REGN5668 (MUC16×CD28) REGN5678 (PSMA×CD28) REGN7075 (EGFR×CD28) Odronextamab (CD20×CD3) REGN5459 (BCMA×CD3) NTLA-2001# (TTR KO CRISP) 	 REGN7257 (IL-2Rg) REGN5381 (NPR1) ALN-HSD [‡] (HSD17B13) REGN6490 (IL-36R) 	PHASE 2 REGEN-COV^ (SARS-CoV-2) Dupilumab* (IL-4R) Cemiplimab* (PD-1) Sarilumab* (IL-6R) Odronextamab (CD20xCD3) Aflibercept (VEGF Trap) REGN5458 (BCMAxCD3) Pozelimab (C5) Pozelimab (C5) Cemdisiran‡ (C5 siRNA) Pozelimab + cemdisiran‡ (C5) Evinacumab (ANGPTL3) Garetosmab (Activin-A) REGN4461 (LEPR) MUUNOLOGY & GENERAL PAIN	 PHASE 3 REGEN-COV[*] (SARS-CoV-2) Cemiplimab[*] (PD-1) Dupilumab[*] (IL-4R) Itepekimab[*] (IL-33) REGN5713-5714-5715 (Betv1) REGN1908-1909 (Feld1) Alirocumab (PCSK9) Fasinumab[†] (NGF) Aflibercept (VEGF Trap)
* In collaboration with Sanofi † In collaboration with Teva and Mitsubis ^ In collaboration with Roche	hi Tanabe [‡] In collaboration with Alnylam [#] In collaboration with Intellia	As of Q2 2021 This slide contains investigational products not yet approved by regu	Ilatory authorities

Multiple Potential Regulatory Submissions: 2021-2023+



Key Upcoming Milestones

EYLEA: Ph2 data readout for High Dose aflibercept formulation in wAMD

Dupixent

- Regulatory action in pediatric asthma (6-11 years)
- Ph3 data readouts for EoE, Prurigo Nodularis, and Pediatric AD

REGEN-COV

- FDA decision to expand EUA to include pre-exposure prophylaxis for appropriate populations
- FDA decision to expand EUA to include hospitalized indication
- Complete rolling BLA and MAA submissions in 2H 2021

Libtayo

Regulatory filings for 1L NSCLC chemotherapy combination, 2L Cervical cancer

Odronextamab (CD20xCD3)


- · Complete enrollment in potentially pivotal Phase 2 in NHL
- Initiate OLYMPIA Phase 3 program, combinations, and subcutaneous formulation

REGN5458 (BCMAxCD3)

- · Complete enrollment in potentially pivotal Phase 2 in Multiple Myeloma
- · Evaluate combinations with standard of care and novel agents; subcutaneous formulation

New Bispecifics: Potential first data for MUC16xCD3 and PSMAxCD28

AD - Atopic Dermatitis NSCLC – Non-Small Cell Lung Cancer NHL – Non-Hodgkin Lymphoma EoE – Eosinophilic Esophagitis EUA – Emergency Use Authorization





Reconciliation of GAAP Net Income to Non-GAAP Net Income and of Net Cash Position

REGENERON PHARMACEUTICALS, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (Unaudited) (In millions, except per share data)

	Three Months Ended June 30,			Six Months Ended June 30,				
		2021 2020			2021			2020
GAAP R&D	\$	714.2	\$	722.0	\$	1,457.1	\$	1,305.9
R&D: Non-cash share-based compensation expense		70.9		56.9		140.6		113.6
R&D: Up-front payments related to license and collaboration agreements				85.0		_		85.0
Non-GAAP R&D	\$	643.3	\$	580.1	\$	1,316.5	\$	1,107.3
GAAP SG&A	\$	414.7	\$	348.3	\$	820.3	\$	715.6
SG&A: Non-cash share-based compensation expense		49.6		38.2		100.4		78.5
SG&A: Litigation contingencies and other		_		8.7		_		28.9
Non-GAAP SG&A	\$	365.1	\$	301.4	\$	719.9	\$	608.2
GAAP COGS	\$	539.4	\$	102.5	\$	722.6	\$	181.3
COGS: Non-cash share-based compensation expense		25.0		8.4		35.4		17.2
COGS: Other		_		0.9		_		0.9
Non-GAAP COGS	\$	514.4	\$	93.2	\$	687.2	\$	163.2
GAAP other income (expense), net	\$	405.6	\$	262.5	\$	545.9	\$	231.0
Other income/expense: Gains on investments		(409.6)		(256.1)		(553.9)		(199.3)
Interest expense: Other		_	_	1.5	_	_	_	1.5
Non-GAAP other income (expense), net	\$	(4.0)	\$	7.9	\$	(8.0)	\$	33.2
GAAP net income	\$	3,098.9	\$	897.3	\$	4,214.1	\$	1,521.9
Total of GAAP to non-GAAP reconciling items above		(264.1)		(56.5)		(277.5)		126.3
Income tax effect of GAAP to non-GAAP reconciling items		60.2		13.6		67.6		(23.2)
Non-GAAP net income	\$	2,895.0	\$	854.4	\$	4,004.2	\$	1,625.0
Non-GAAP net income per share - basic	\$	27.57	\$	7.80	\$	38.06		14.81
Non-GAAP net income per share - diluted	\$	25.80	\$	7.16	\$	35.72		13.70
Shares used in calculating:								
Non-GAAP net income per share - basic		105.0		109.6		105.2		109.7
Non-GAAP net income per share - diluted		112.2		119.3		112.1		118.6

REGENERON PHARMACEUTICALS, INC. RECONCILIATION OF NET CASH POSITION (Unaudited) (In millions)

	June 30, 2021		cember 31, 2020
Cash and marketable securities	\$ 7,811.1	\$	6,722.6
Long-term debt	1,979.2		1,978.5
Finance lease liabilities	718.4		717.2
Net cash position	\$ 5,113.5	\$	4,026.9

REGENERON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In millions)

	June 30,		cember 31,
	 2021		2020
Assets:			
Cash and marketable securities	\$ 7,811.1	\$	6,722.6
Accounts receivable, net	6,998.6		4,114.7
Inventories	1,983.9		1,916.6
Property, plant, and equipment, net	3,358.5		3,221.6
Deferred tax assets	746.6		858.9
Other assets	 587.2		328.9
Total assets	\$ 21,485.9	\$	17,163.3
Liabilities and stockholders' equity:			
Accounts payable, accrued expenses, and other liabilities	\$ 3,090.3	\$	2,806.8
Finance lease liabilities	718.4		717.2
Deferred revenue	570.7		635.5
Long-term debt	1,979.2		1,978.5
Stockholders' equity	15,127.3		11,025.3
Total liabilities and stockholders' equity	\$ 21,485.9	\$	17,163.3

27